You are here

Article Text

Article menu
Download PDFPDF
Mailbox
No evidence for severe retinopathy of prematurity following sildenafil
  1. C M Pierce1,
  2. A J Petros1,
  3. A R Fielder2
  1. 1Neonatal Intensive Care Unit, Great Ormond Street Hospital, London WC1N 3JH, UK
  2. 2Department of Visual Neuroscience, Imperial College London, Room 9L02, Charing Cross Campus, St Dunstan’s Road, London W6 8RP, UK
  1. Correspondence to: A R Fielder Department of Visual Neuroscience, Imperial College London, Room 9L02, Charing Cross Campus, St Dunstan’s Road, London W6 8RP, UK; a.fielderimperial.ac.uk

https://doi.org/10.1136/bjo.2004.054023

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Marsh and colleagues1 raise the spectre of a possible association between the use of sildenafil and the development of retinopathy of prematurity (ROP) in a baby of 26 weeks gestation with pulmonary hypertension. We are concerned that this report offers no real evidence for its claims and that a potentially lifesaving agent is being unfairly maligned.

    The report describes the use of intravenous sildenafil of unspecified dose for 16 days in a 525 g preterm infant with a very difficult intensive care course. The …

    View Full Text

    Footnotes

    • Conflict of interest: The authors have acted in an independent consultant capacity (CMP, AJP, ARF) and are in receipt of financial support in the form of a research grant (CMP, AJP) from the manufacturers of sildenafil, Pfizer Ltd.